Soiken Holdings Inc.【JP:2385】Stock Price

Soken Medical Holdings is a healthcare-related holding company engaged in research and development of biomarker evaluation systems, clinical assessment services using these systems, health support services, and development and sales of cosmetics and nutritional supplements, as well as functional ingredient development. The company is built on university-derived biomarker technology and operates two core business pillars: objective evaluation systems for the efficacy and safety of food and pharmaceutical products, and consumer-facing products.

The company's primary customers include food and pharmaceutical companies, health insurance associations and medical institutions, as well as general consumers through mail-order and department store channels. Revenue is primarily generated from contracted evaluation testing, biomarker licensing fees, sales of cosmetics and supplements, and fees from contracted health screening and preventive services.

The business is divided into five segments: biomarker evaluation systems, healthcare support, cosmetics, nutritional supplements, and functional ingredient development. The biomarker evaluation systems business conducts clinical evaluation testing and develops and supplies biomarkers. The healthcare support business provides contracted health screening and preventive services. The cosmetics business handles direct sales and wholesale of proprietary brands using placenta extract. The nutritional supplements business sells proprietary products such as imidapeptide. The functional ingredient development division pursues development of ingredients such as lactoferrin, technology licensing, and exploration of pharmaceutical candidates.

The company aims to enhance corporate value and achieve stable growth. Starting from its management philosophy of "commercializing medical science research outcomes to contribute to people's healthy and safe lives," the company has set business foundation strengthening and scale expansion as management objectives. In the fiscal year ended June 2024, the company recorded an operating loss due to declining cosmetics sales and reduced profitability in the health supplement business. However, positioning the fiscal year ended June 2025 as a structural reform period, the company is pursuing profitability improvements through new management initiatives and strategic investments, achieving operating profit gains across multiple business segments and significantly reducing consolidated operating losses.

The company positions research and development investment as the core of its differentiation strategy. Building on university-derived biomarker technology, the company develops proprietary products based on clinical data using functional ingredients such as "imidapeptide" (which received functional claim approval in April 2015) from its fatigue assessment project and lactoferrin. By advancing joint research with universities, securing patents, and registering trademarks and designs, the company aims to differentiate through scientifically-backed products rather than competing solely on distribution channels.

As part of new market development and business expansion, the company is building a "comprehensive healthcare platform." By combining online health consultations, telemedicine, disease management, mail-in testing, and personal health records with sales of health supplements, over-the-counter pharmaceuticals, and cosmetics, the company aims to provide services available "anytime, anywhere." Through a capital and business partnership with a Chinese distribution company (February 2019), the company is advancing joint development of supplements for Asia and leveraging e-commerce sales networks. Simultaneously, the company is concentrating management resources on high-growth medical sectors through cosmetics market withdrawal from China, business portfolio restructuring, and workforce optimization via voluntary retirement programs.

The company is advancing technological innovation through healthcare digitalization (medical DX) and evidence-based algorithm development. Premised on data security, regulatory compliance, and ethical frameworks, the company aims to enhance service precision through clinical trials and biomarker standardization, strengthening the evidence base for algorithms and diagnostic support. Additionally, the company actively pursues mergers, acquisitions, and business partnerships in the medical DX sector to enrich platform content, pursuing sustainable growth through commercializing research outcomes and expanding licensing revenue.